Dr. Anthony F. Shields
Claim this profileBarbara Ann Karmanos Cancer Institute
Studies Solid Tumors
Studies Tumors
20 reported clinical trials
62 drugs studied
Area of expertise
1Solid Tumors
Stage IV
Stage III
dMMR positive
2Tumors
Stage IV
Stage III
dMMR positive
Affiliated Hospitals
Clinical Trials Anthony F. Shields is currently running
TAB004 + Toripalimab
for Solid Cancers
The primary objective is to assess the safety and tolerability of TAB004 as monotherapy and in combination with toripalimab in subjects with selected advanced solid malignancies, including lymphoma, and to evaluate the recommended Phase 2 dose. The secondary objectives are to: 1) describe the pharmacokinetic (PK) profile of TAB004 monotherapy and in combination with toripalimab and to describe the PK profile of toripalimab when administered with TAB004, 2) evaluate antitumor activity of TAB004 monotherapy and in combination with toripalimab; and 3) determine the immunogenicity of TAB004 monotherapy and in combination with toripalimab and to determine the immunogenicity of toripalimab when administered with TAB004. The exploratory objectives are to: 1) evaluate pharmacodynamic effects of TAB004 on its target receptor BTLA, as well as effects on the immune system; 2) evaluate biomarkers that may correlate with activity of TAB004 as monotherapy and in combination with toripalimab; 3) evaluate the utility of BTLA ligand, herpesvirus-entry mediator (HVEM), and additional exploratory biomarkers that could aid in selection of appropriate subjects for TAB004 monotherapy and in combination with toripalimab.
Recruiting1 award Phase 110 criteria
ABSK121-NX
for Solid Tumors
This trial tests a new drug called ABSK121-NX for patients with advanced solid tumors. It aims to find the safest dose and see if the drug can help reduce or control the tumors.
Recruiting1 award Phase 1
More about Anthony F. Shields
Clinical Trial Related4 years of experience running clinical trials · Led 20 trials as a Principal Investigator · 11 Active Clinical TrialsTreatments Anthony F. Shields has experience with
- Ipilimumab
- Capecitabine
- Fluorouracil
- Gemcitabine
- Nivolumab
- Leucovorin
Breakdown of trials Anthony F. Shields has run
Solid Tumors
Tumors
Colorectal Cancer
Pancreatic Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Anthony F. Shields specialize in?
Anthony F. Shields focuses on Solid Tumors and Tumors. In particular, much of their work with Solid Tumors has involved Stage IV patients, or patients who are Stage III.
Is Anthony F. Shields currently recruiting for clinical trials?
Yes, Anthony F. Shields is currently recruiting for 11 clinical trials in Detroit Michigan. If you're interested in participating, you should apply.
Are there any treatments that Anthony F. Shields has studied deeply?
Yes, Anthony F. Shields has studied treatments such as Ipilimumab, Capecitabine, Fluorouracil.
What is the best way to schedule an appointment with Anthony F. Shields?
Apply for one of the trials that Anthony F. Shields is conducting.
What is the office address of Anthony F. Shields?
The office of Anthony F. Shields is located at: Barbara Ann Karmanos Cancer Institute, Detroit, Michigan 48201 United States. This is the address for their practice at the Barbara Ann Karmanos Cancer Institute.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.